Frontier Science Foundation, Hellas Report issue

Foundation Phase 2 Phase 3

Organization Overview

First Clinical Trial
2014
NCT02046733
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (3)

gemcitabine (gemzar) (1 trial)

pembrolizumab (keytruda) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 2 Trials (2)

ipilimumab (yervoy) (1 trial)

nivolumab (opdivo) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Mesothelioma (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5